Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.19.3
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities    
Net income $ 79 $ 977
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 561 333
Share-based compensation expense 94 89
Non-cash interest expense 122 52
Amortization of debt issuance costs, deferred commitment fees, premium and discount 71 53
Non-cash operating lease costs 251 0
Loss on modification or extinguishment of debt 27 27
Total losses on derivatives, net 22 17
Net cash provided by (used for) settlement of derivative instruments 108 (54)
Impairment expense and loss on disposal of assets 7 8
Loss on equity method investments 88 0
Other (2) (5)
Changes in operating assets and liabilities:    
Accounts and other receivables (5) 114
Inventory 35 (56)
Other current assets (45) (35)
Accounts payable and accrued liabilities (82) (23)
Deferred revenue 33 8
Operating lease liabilities (263) 0
Finance lease liabilities 1 0
Other, net (10) (1)
Net cash provided by operating activities 1,092 1,504
Cash flows from investing activities    
Property, plant and equipment, net (2,587) (2,712)
Investment in equity method investment (70) (25)
Other (1) 15
Net cash used in investing activities (2,658) (2,722)
Cash flows from financing activities    
Proceeds from issuances of debt 4,420 3,443
Repayments of debt (2,237) (1,385)
Debt issuance and deferred financing costs (38) (53)
Debt extinguishment costs (4) (16)
Distributions and dividends to non-controlling interest (439) (435)
Payments related to tax withholdings for share-based compensation (19) (10)
Repurchase of common stock (159) 0
Other 3 (7)
Net cash provided by financing activities 1,527 1,537
Net increase (decrease) in cash, cash equivalents and restricted cash (39) 319
Cash, cash equivalents and restricted cash—beginning of period 3,156 2,613
Cash, cash equivalents and restricted cash—end of period $ 3,117 $ 2,932